Neuroscience

Congress Materials – American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM 2026)

2025 American Association of Neuromuscular & Electrodiagnostic Medicine | Sep 29-Oct 2 | Orlando, FL

This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.

Acetylcholine Receptor-Autoantibody Detection and Therapeutic Assessment of Nipocalimab in Seronegative Patients with Myasthenia Gravis in VIVACITY-MG3

Silke Miller, Gallen Triana-Baltzer, Hans Frykman, Anna Mammel, Pankaj Kumar, Marie Fitzgibbon, Michael Kutch, Laura Green, Sindhu Ramchandren, Matteo Gastaldi

Congress Materials – American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM 2026)

Acetylcholine Receptor-Autoantibody Detection and Therapeutic Assessment of Nipocalimab in Seronegative Patients with Myasthenia Gravis in VIVACITY-MG3

Assessing the Relationship Between IgG Levels and Infection Rate in Nipocalimab-Treated Patients with Generalized Myasthenia Gravis (VIVACITY-MG3)

Assessing the Relationship Between Immunoglobulin G Level and Efficacy of Nipocalimab Measured Using Myasthenia Gravis Activities of Daily Living Scale

Assessment of Health-Related Quality of Life Measures in Anti-Muscle-Specific Tyrosine Kinase Antibody-Positive Patients With Generalized Myasthenia Gravis: Post Hoc Analysis of the VIVACITY-MG3 Study

Assessment of Sustained Health-Related Quality of Life in Phase 3 VIVACITY-MG3 Trial of Nipocalimab Versus Placebo in Generalized Myasthenia Gravis

Corticosteroid Usage in Patients With Generalized Myasthenia Gravis Receiving Nipocalimab: Phase 3 VIVACITY-MG3 Open-Label Extension

Corticosteroid Use in Nipocalimab-Treated Japanese Patients with Generalized Myasthenia Gravis: Phase 3 VIVACITY-MG3 Open-Label Extension Study

Digital Gait Characteristics as Indicators of Muscle Strength in Chronic Inflammatory Demyelinating Polyneuropathy

Effect of Nipocalimab on Pathogenic IgG and Circulating Immune Complex Levels: A Role in Myasthenia Gravis Activities of Daily Living Improvement in Patients With Generalized Myasthenia Gravis

Effect of Nipocalimab on Pathogenic IgG and Complement Markers in Patients with Seropositive Generalized Myasthenia Gravis: Exploratory Analysis in the VIVACITY-MG3 Study

Effect of Nipocalimab on Sustained Disease Control During Infections: Post-Hoc Analysis of the VIVACITY-MG3 Study in Myasthenia Gravis

Effect of Nipocalimab on Sustained Disease Control in Anti-Muscle-Specific Tyrosine Kinase-Antibody-Positive Patients With Generalized Myasthenia Gravis: A Post Hoc Analysis of the VIVACITY-MG3 Study

Efficacy and Safety of Nipocalimab: Switch From 15-mg/kg Every-2-Weeks to 30 mg/kg Every-4-Weeks (VIVACITY-MG3 Open-Label Extension)

Efficacy of Nipocalimab in Adult Patients with None-to-Mild Ocular Manifestations of Generalized Myasthenia Gravis in the Phase 3 VIVACITY-MG3 Study

Efficacy of Nipocalimab in Patients Early in Their Disease Course of Generalized Myasthenia Gravis: Post Hoc Analysis of VIVACITY-MG3

Efficacy of Nipocalimab in Patients with Lower Baseline Score of Myasthenia Gravis Activities of Daily Living in VIVACITY-MG3 Study

Factors Associated With Recurrent Clinical Events Among Pediatric Generalized Myasthenia Gravis Patients in the United States

Frequency of Sustained Response to Nipocalimab Versus Placebo Based on Myasthenia Gravis Activities of Daily Living and Quantitative Myasthenia Gravis Scales in the Phase 3 VIVACITY-MG3 Study

Healthcare Costs in Commercially Insured Pediatric Patients with Generalized Myasthenia Gravis in the United States

Immunogenicity Assessment With Nipocalimab Treatment in Patients With Generalized Myasthenia Gravis

Indirect Comparison of Nipocalimab Safety Versus Neonatal Fc Receptor Blockers, C5 Complement Inhibitors, Rituximab and Intravenous Immunoglobulin in Generalized Myasthenia Gravis

Lived Experiences of Chronic Inflammatory Demyelinating Polyneuropathy: Global Patient and Caregiver Perspectives

Long-Term Safety and Efficacy of Nipocalimab: Approximately 2 Years of Follow-Up Results From the Open-Label Extension Phase of VIVACITY-MG3 Study

Nipocalimab in Chronic Inflammatory Demyelinating Polyneuropathy: Updated Diagnostic Adjudication Findings From the Phase 2/3 ARISE Study

Pregnancy Enhanced Tracking with Neonatal and Infant Assessment: Design of a Safety Study For Nipocalimab in Generalized Myasthenia Gravis

Quality of Life in Patients With Generalized Myasthenia Gravis Achieving Sustained Versus Transient Clinical Outcomes in the Phase 3 VIVACITY-MG3 Trial

Quality of Life in Patients with Generalized Myasthenia Gravis Achieving Sustained Versus Transient Minimal Symptom Expression in the Phase 3 VIVACITY-MG3 Trial

Retrospective Review of Treatment Switches to Nipocalimab in Generalized Myasthenia Gravis: Real World Health Care Provider Perspectives

Symptom Severity Assessment Using Myasthenia Gravis Activities of Daily Living in Active-Treatment

Connect with us

Connect with us